论文信息 - CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548 - 字舞流文

CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548

Jennie W. Taylor | M. Weller | J. Honnorat | A. Idbaih | A. Omuro | G. Finocchiaro | A. Wick | J. Steinbach | D. Warad | J. Baehring | K. Petrecca | M. Lim | G. Ansstas | R. Raval | A. Sumrall | L. Ashby | F. D. De Vos | Michelle Lee | D. Reardon | R. Slepetis | M. Roberts